ArticleScientific reports2021
Donepezil for mild cognitive impairment in Parkinson's disease.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Effects of immersive virtual reality and adaptive cognitive training on cognition and function in parkinson's disease mild cognitive impairment: a randomized clinical trial.Scientific reports · 2026Trial
- An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.JAMA neurology · 2025Trial
- Effects of psychological nursing in Parkinson's related depression patients undergoing functional magnetic resonance imaging: A randomized controlled trial.World journal of clinical cases · 2024Trial
- Donepezil Research in Cognitive Impairment: A Bibliometric and Scientometric Analysis of Global Trends and Pharmacological Perspectives.Brain and behavior · 2026Article
- Consensus Molecules Associated with Parkinson's Disease.Neurology international · 2026Review
- Effectiveness of non-pharmacological interventions for cognitive impairment in Parkinson's disease: systematic review protocol.BJPsych open · 2025Article
- Cortical hypometabolism in Parkinson's disease is linked to cholinergic basal forebrain atrophy.Molecular psychiatry · 2025Article
- Clinical efficacy of donepezil combined with nerve growth factor in the treatment of patients with Parkinson's disease dementia and its impact on adiponectin and soluble tumor necrosis factor-alpha receptor-1.Pakistan journal of medical sciences · 2025Article
- Brain fog in Parkinson's disease: unraveling mechanisms and measuring impact.Frontiers in neurology · 2025Article
- Approaches for treating neuropsychiatric symptoms in Parkinson's disease: a narrative review.Therapeutic advances in neurological disorders · 2025Review
- Clinical effect of donepezil hydrochloride in the treatment of Parkinson's disease patients: a meta-analysis.American journal of translational research · 2025Review
- German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson's disease: new spotlights on diagnostic procedures and non-pharmacological interventions.Journal of neurology · 2024Article
- Cognition and Activity of Daily Living Function in people with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Effect of Butylphthalide soft capsules on cognitive function and dementia-related factors in elderly patients with Parkinson's disease dementia during the COVID-19 pandemic.American journal of translational research · 2024Article
- Associations between cognitive screening performance and motor symptoms in Parkinson's disease:a systematic review and meta-analysis.Dementia & neuropsychologia · 2024Review
- The Tale of DJ-1 (PARK7): A Swiss Army Knife in Biomedical and Psychological Research.International journal of molecular sciences · 2023Review
- Fountain of youth-Targeting autophagy in aging.Frontiers in aging neuroscience · 2023Review
- Quantitative electroencephalographic analysis of delirium tremens development following alcohol-withdrawal seizure based on a small number of male cases.Brain and behavior · 2022Article
- Distinct atrophy of septal nuclei in Parkinson's disease.Clinical parkinsonism & related disorders · 2022Article
- Prediction model for potential depression using sex and age-reflected quantitative EEG biomarkers.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson's disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks. The primary outcome measures were the Korean version of Mini-Mental State Exam and Montreal Cognitive Assessment scores. Secondary outcome measures were the Clinical Dementia Rating, Unified Parkinson's Disease Rating Scale part III, Clinical Global Impression scores. Progression of dementia was assessed at 48-week. Comprehensive neuropsychological tests and electroencephalography (EEG) were performed at baseline and after 48 weeks. The spectral power ratio of the theta to beta2 band (TB2R) in the electroencephalogram was analyzed. There was no significant difference in the primary and secondary outcome measures between the two groups. However, the treatment group showed a significant decrease in TB2R at bilateral frontotemporoparietal channels compared to the control group. Although we could not demonstrate improvements in the cognitive functions, donepezil treatment had a modulatory effect on the EEG in PD-MCI patients. EEG might be a sensitive biomarker for detecting changes in PD-MCI after donepezil treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.